BMS’ Reblozyl Approved in Canada for Beta Thalassemia

Bristol Myers Squibb and Acceleron Pharma have received Health Canada’s approval for Reblozyl (luspatercept) for the treatment of adults with red blood cell transfusion-dependent anemia associated with beta-thalassemia, a rare genetic blood disorder.

The approval was based on data from a phase 3 study in which patients treated with Reblozyl required fewer blood cell transfusions, achieving a reduction of at least two units from weeks 13 to 24 as compared to participants given a placebo.

Reblozyl is currently approved in the U.S. and Europe for the treatment of anemia in patients with beta thalassemia.